Cargando…
High‐throughput screening assays for SARS‐CoV‐2 drug development: Current status and future directions
In response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, a panel of assays has been developed and applied to screen collections of approved and investigational drugs for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity in a quantitative high-throughput scree...
Autores principales: | Xu, Tuan, Zheng, Wei, Huang, Ruili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Ltd. ;, Distributed by Virgin Mailing and Distribution
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146264/ https://www.ncbi.nlm.nih.gov/pubmed/34048893 http://dx.doi.org/10.1016/j.drudis.2021.05.012 |
Ejemplares similares
-
Repurposing drugs as COVID-19 therapies: A toxicity evaluation
por: Ngan, Deborah K., et al.
Publicado: (2022) -
Drug repurposing against SARS-CoV-2 using computational approaches
por: Kumar, Sumit, et al.
Publicado: (2022) -
The current status of COVID-19 vaccines. A scoping review
por: Rueda-Fernández, Manuel, et al.
Publicado: (2022) -
Nanosponges: An overlooked promising strategy to combat SARS-CoV-2
por: Mostafavi, Ebrahim, et al.
Publicado: (2022) -
Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2
por: Ho, Gilbert, et al.
Publicado: (2021)